Short-term treatment with tolfenamic acid improves cognitive functions in alzheimer's disease mice

Neurobiology of Aging

Volumn 34, Issue 10, 2013, Pages 2421-2430

  Subaiea, Gehad M ^a   Adwan, Lina I ^a   Ahmed, Aseef H ^a   Stevens, Karen E ^b   Zawia, Nasser H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

AD transgenic mouse model; Alzheimer's disease; Learning and memory; Morris water maze; Tolfenamic acid; Y maze

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CORN OIL; MESSENGER RNA; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEMIZYGOTE; LONG TERM MEMORY; LOW DRUG DOSE; MAZE TEST; MEMORY DISORDER; MOUSE; NEUROPATHOLOGY; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; SPATIAL LEARNING; TRANSGENIC MOUSE; TREATMENT DURATION; WORKING MEMORY;

AD TRANSGENIC MOUSE MODEL; ALZHEIMER'S DISEASE; LEARNING AND MEMORY; MORRIS WATER MAZE; TOLFENAMIC ACID; Y-MAZE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; MAZE LEARNING; MEMORY DISORDERS; MEMORY, LONG-TERM; MEMORY, SHORT-TERM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NOOTROPIC AGENTS; ORTHO-AMINOBENZOATES; SP1 TRANSCRIPTION FACTOR;

EID: 84879881041     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.04.002     Document Type: Article

References (75)

1. Abdelrahim M., Baker C.H., Abbruzzese J.L., Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J.Natl. Cancer Inst. 2006, 98:855-868.
2. Adwan L.I., Basha R., Abdelrahim M., Subaiea G.M., Zawia N.H. Tolfenamic acid interrupts the de novo synthesis of the beta-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway. Curr. Alzheimer Res. 2011, 8:385-392.
3. Andersen K., Launer L.J., Ott A., Hoes A.W., Breteler M.M., Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995, 45:1441-1445.
4. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
5. Basha M.R., Wei W., Bakheet S.A., Benitez N., Siddiqi H.K., Ge Y.W., Lahiri D.K., Zawia N.H. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J.Neurosci. 2005, 25:823-829.
6. Basha R., Ingersoll S.B., Sankpal U.T., Ahmad S., Baker C.H., Edwards J.R., Holloway R.W., Kaja S., Abdelrahim M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol. Oncol. 2011, 122:163-170.
7. Berg L., McKeel D.W., Miller J.P., Baty J., Morris J.C. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch. Neurol. 1993, 50:349-358.
8. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 1997, 18:351-357.
9. Brock B., Basha R., DiPalma K., Anderson A., Harry G.J., Rice D.C., Maloney B., Lahiri D.K., Zawia N.H. Co-localization and distribution of cerebral APP and SP1 and its relationship to amyloidogenesis. J.Alzheimers Dis. 2008, 13:71-80.
10. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., Wong P.C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 2001, 4:233-234.
11. Christensen M.A., Zhou W., Qing H., Lehman A., Philipsen S., Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol. Cell Biol. 2004, 24:865-874.
12. Citron B.A., Dennis J.S., Zeitlin R.S., Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J.Neurosci. Res. 2008, 86:2499-2504.
13. Colon J., Basha M.R., Madero-Visbal R., Konduri S., Baker C.H., Herrera L.J., Safe S., Sheikh-Hamad D., Abudayyeh A., Alvarado B., Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest. New Drugs 2011, 29:41-51.
14. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J.Neurosci. 2000, 20:558-567.
15. Cote S., Carmichael P.H., Verreault R., Lindsay J., Lefebvre J., Laurin D. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2012, 8:219-226.
16. Daynes R.A., Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2002, 2:748-759.
17. Docagne F., Gabriel C., Lebeurrier N., Lesne S., Hommet Y., Plawinski L., Mackenzie E.T., Vivien D. Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. Biochem. J. 2004, 383(Pt 2):393-399.
18. Duff K., Suleman F. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development?. Brief Funct. Genomic Proteomic 2004, 3:47-59.
19. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003, 327:128.
20. Finder V.H., Glockshuber R. Amyloid-beta aggregation. Neurodegener. Dis. 2007, 4:13-27.
21. Frankland P.W., Bontempi B. The organization of recent and remote memories. Nat. Rev. Neurosci. 2005, 6:119-130.
22. Gotz J., Ittner A., Ittner L.M. Tau-targeted treatment strategies in Alzheimer's disease. Br. J. Pharmacol. 2012, 165:1246-1259.
23. Gulinello M., Gertner M., Mendoza G., Schoenfeld B.P., Oddo S., LaFerla F., Choi C.H., McBride S.M., Faber D.S. Validation of a 2-day water maze protocol in mice. Behav. Brain Res. 2009, 196:220-227.
24. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
25. Harrington C.R. The molecular pathology of Alzheimer's disease. Neuroimaging Clin. N. Am. 2012, 22:11-22.
26. Heicklen-Klein A., Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J.Neurochem. 2000, 75:1408-1418.
27. Heneka M.T., Reyes-Irisarri E., Hull M., Kummer M.P. Impact and therapeutic potential of PPARs in Alzheimer's disease. Curr. Neuropharmacol. 2011, 9:643-650.
28. Herrmann N., Chau S.A., Kircanski I., Lanctot K.L. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 2011, 71:2031-2065.
29. Hock B.J., Lamb B.T. Transgenic mouse models of Alzheimer's disease. Trends Genet. 2001, 17:S7-S12.
30. Hock B.J., Lattal K.M., Kulnane L.S., Abel T., Lamb B.T. Pathology associated memory deficits in Swedish mutant genome-based amyloid precursor protein transgenic mice. Curr. Aging Sci. 2009, 2:205-213.
31. in t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N.Engl. J. Med. 2001, 345:1515-1521.
32. King D.L., Arendash G.W., Crawford F., Sterk T., Menendez J., Mullan M.J. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 1999, 103:145-162.
33. Konduri S., Colon J., Baker C.H., Safe S., Abbruzzese J.L., Abudayyeh A., Basha M.R., Abdelrahim M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol. Cancer Ther. 2009, 8:533-542.
34. Kroth H., Ansaloni A., Varisco Y., Jan A., Sreenivasachary N., Rezaei-Ghaleh N., Giriens V., Lohmann S., Lopez-Deber M.P., Adolfsson O., Pihlgren M., Paganetti P., Froestl W., Nagel-Steger L., Willbold D., Schrader T., Zweckstetter M., Pfeifer A., Lashuel H.A., Muhs A. Discovery and structure activity relationship of small molecule inhibitors of toxic beta-amyloid-42 fibril formation. J.Biol. Chem. 2012, 287:34786-34800.
35. Kulnane L.S., Lamb B.T. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol. Dis. 2001, 8:982-992.
36. Laczo J., Vlcek K., Vyhnalek M., Vajnerova O., Ort M., Holmerova I., Tolar M., Andel R., Bojar M., Hort J. Spatial navigation testing discriminates two types of amnestic mild cognitive impairment. Behav. Brain Res. 2009, 202:252-259.
37. Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci. Biobehav. Rev. 2002, 26:91-104.
38. Lamb B.T., Bardel K.A., Kulnane L.S., Anderson J.J., Holtz G., Wagner S.L., Sisodia S.S., Hoeger E.J. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat. Neurosci. 1999, 2:695-697.
39. Lamb B.T., Call L.M., Slunt H.H., Bardel K.A., Lawler A.M., Eckman C.B., Younkin S.G., Holtz G., Wagner S.L., Price D.L., Sisodia S.S., Gearhart J.D. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum. Mol. Genet. 1997, 6:1535-1541.
40. Lamb B.T., Sisodia S.S., Lawler A.M., Slunt H.H., Kitt C.A., Kearns W.G., Pearson P.L., Price D.L., Gearhart J.D. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nat. Genet. 1993, 5:22-30.
41. Lehman E.J., Kulnane L.S., Lamb B.T. Alterations in beta-amyloid production and deposition in brain regions of two transgenic models. Neurobiol. Aging 2003, 24:645-653.
42. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J.Biol. Chem. 1997, 272:3406-3410.
43. Lindsay J., Laurin D., Verreault R., Hebert R., Helliwell B., Hill G.B., McDowell I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 2002, 156:445-453.
44. Mandrekar-Colucci S., Karlo J.C., Landreth G.E. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J.Neurosci. 2012, 32:10117-10128.
45. Martinez-Coria H., Green K.N., Billings L.M., Kitazawa M., Albrecht M., Rammes G., Parsons C.G., Gupta S., Banerjee P., LaFerla F.M. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am. J. Pathol. 2010, 176:870-880.
46. Matsuo A., Walker D.G., Terai K., McGeer P.L. Expression of CD43 in human microglia and its downregulation in Alzheimer's disease. J.Neuroimmunol. 1996, 71:81-86.
47. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
48. McKee A.C., Carreras I., Hossain L., Ryu H., Klein W.L., Oddo S., LaFerla F.M., Jenkins B.G., Kowall N.W., Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008, 1207:225-236.
49. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-866.
50. Morishima-Kawashima M., Oshima N., Ogata H., Yamaguchi H., Yoshimura M., Sugihara S., Ihara Y. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am. J. Pathol. 2000, 157:2093-2099.
51. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
52. Nelson P.T., Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Del Tredici K., Duyckaerts C., Frosch M.P., Haroutunian V., Hof P.R., Hulette C.M., Hyman B.T., Iwatsubo T., Jellinger K.A., Jicha G.A., Kovari E., Kukull W.A., Leverenz J.B., Love S., Mackenzie I.R., Mann D.M., Masliah E., McKee A.C., Montine T.J., Morris J.C., Schneider J.A., Sonnen J.A., Thal D.R., Trojanowski J.Q., Troncoso J.C., Wisniewski T., Woltjer R.L., Beach T.G. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J.Neuropathol. Exp. Neurol. 2012, 71:362-381.
53. Ozudogru S.N., Lippa C.F. Disease modifying drugs targeting beta-amyloid. Am. J. Alzheimers Dis. Other Demen. 2012, 27:296-300.
54. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N.Engl. J. Med. 2010, 362:329-344.
55. Reaume A.G., Howland D.S., Trusko S.P., Savage M.J., Lang D.M., Greenberg B.D., Siman R., Scott R.W. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. J.Biol. Chem. 1996, 271:23380-23388.
56. Reddy P.H., Manczak M., Mao P., Calkins M.J., Reddy A.P., Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J.Alzheimers Dis. 2010, 20(suppl 2):S499-S512.
57. Roberson E.D., Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314:781-784.
58. Santpere G., Nieto M., Puig B., Ferrer I. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. Neurosci. Lett. 2006, 397:30-34.
59. Sastre M., Dewachter I., Landreth G.E., Willson T.M., Klockgether T., van Leuven F., Heneka M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J.Neurosci. 2003, 23:9796-9804.
60. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:443-448.
61. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
62. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B., Younkin S.G. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258:126-129.
63. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
64. Subaiea G.M., Alansi B.H., Serra D.A., Alwan M., Zawia N.H. The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms. Curr. Alzheimer Res. 2011, 8:860-867.
65. Teixeira C.M., Pomedli S.R., Maei H.R., Kee N., Frankland P.W. Involvement of the anterior cingulate cortex in the expression of remote spatial memory. J.Neurosci. 2006, 26:7555-7564.
66. Urbanc B., Cruz L., Buldyrev S.V., Havlin S., Irizarry M.C., Stanley H.E., Hyman B.T. Dynamics of plaque formation in Alzheimer's disease. Biophys. J. 1999, 76:1330-1334.
67. Van Dam D., Coen K., De Deyn P.P. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacology (Berl) 2008, 197:37-43.
68. Vlad S.C., Miller D.R., Kowall N.W., Felson D.T. Protective effects ofNSAIDs on the development of Alzheimer disease. Neurology 2008, 70:1672-1677.
69. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
70. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. Asubset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216.
71. Wu J., Basha M.R., Brock B., Cox D.P., Cardozo-Pelaez F., McPherson C.A., Harry J., Rice D.C., Maloney B., Chen D., Lahiri D.K., Zawia N.H. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J.Neurosci. 2008, 28:3-9.
72. Yue L., Mazzone T. Peroxisome proliferator-activated receptor {gamma} stimulation of adipocyte ApoE gene transcription mediated by the liver receptor X pathway. J.Biol. Chem. 2009, 284:10453-10461.
73. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Breitner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002, 59:880-886.
74. Zhang H., Ma Q.L., Zhang Y.W., Xu H.X. Proteolytic processing of Alzheimer's ss-amyloid precursor protein. J.Neurochem. 2012, 120:9-21.
75. Zhou Y., Su Y., Li B., Liu F., Ryder J.W., Wu X., Gonzalez-DeWhitt P.A., Gelfanova V., Hale J.E., May P.C., Paul S.M., Ni B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003, 302:1215-1217.